
[CLAIMS]

[Claim 1]

Use of a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for simultaneously alleviating skin hardening and improving lung function of systemic sclerosis-associated interstitial lung disease (SSc-ILD).

[Chemical Formula 1]



.

[Claim 2]

The use according to claim 1, wherein:

the pharmaceutically acceptable salt is hydrochloride.

[Claim 3]

The use according to claim 1, wherein:

the medicament further comprises other active ingredient used for the prevention or treatment of systemic sclerosis.

[Claim 4]

The use according to claim 1, wherein:

the other active ingredient used for the prevention or treatment of systemic sclerosis is Nintedanib or Tocilizumab.